The Binding Site

The Binding Site The Specialist Protein Company

Binding Site, Part of Thermo Fisher Scientific, is committed to improving patient lives worldwide through education, collaboration and innovation. Binding Site provide diagnostic solutions that help doctors, clinicians and laboratory researchers across the globe diagnose and monitor blood cancers and immune system disorders. Founded by researchers at the University of Birmingham, Binding Site has continued to build on its strong scientific foundations, supporting research and development within our field and responding to the changing needs of patients, researchers and clinicians for over 30 years. We are committed to working in collaboration with our partners and customers to lead the way in specialized medical diagnostics, ensuring we continue to make a difference together.

19/01/2026

In the fast-paced world of clinical diagnostics, laboratories are under unprecedented pressure with rising workloads and staffing challenges. The Optilite® Analyser delivers highly accurate protein testing, allowing clinicians to identify conditions sooner and monitor patients through their journey.

Watch the video to hear Astrid Coppens, CEO Sonic HealthCare Belgium, discuss how implementing the Optilite Analyser led to improvements in lab switching and doubled the reporting time.

Learn more 👉 http://spr.ly/6182CNtLp

15/01/2026

While Monoclonal Gammopathy of Undetermined Significance (MGUS) is often discussed in relation to its progression to multiple myeloma, it's important to note that some patients can develop renal disorders without progression to Multiple Myeloma.

Dive deeper into this topic and discover more about Monoclonal Gammopathies of Renal Significance in this white paper 👉 http://spr.ly/6187CSUoT

12/01/2026

Monoclonal Gammopathy of Undetermined Significance (MGUS) is often encountered by primary care providers, but what is MGUS?

Discover why this condition, a precursor to multiple myeloma, is important and why patients require monitoring. Learn more about MGUS and its significance here 👉 http://spr.ly/6187CSoit

07/01/2026

Kidneys, bones, nervous system, eyes, skin and other organs can be affected by plasma cell dyscrasias and monoclonal protein production and deposition.

For some patients with Monoclonal Gammopathy of Undetermined Significance (MGUS), this can lead to Monoclonal Gammopathy of Clinical Significance (MGCS).

Discover why monitoring MGUS patients is crucial to detect and manage these serious conditions. Learn more here 👉 http://spr.ly/6182CWa3n

Did you know that Monoclonal Gammopathy of Undetermined Significance (MGUS) is the most common monoclonal gammopathy? MG...
05/01/2026

Did you know that Monoclonal Gammopathy of Undetermined Significance (MGUS) is the most common monoclonal gammopathy?

MGUS can progress to Multiple Myeloma, making regular monitoring crucial. This condition impacts 1 in 30 people over 50. Stay informed and learn more about MGUS and its implications. 👉 http://spr.ly/6183CYXR7

19/12/2025

From all of us at The Binding Site, we wish you a happy, healthy, and joyful holiday season!

ASH 2025 brought together the global hematology community, providing us the opportunity to exchange knowledge and share ...
18/12/2025

ASH 2025 brought together the global hematology community, providing us the opportunity to exchange knowledge and share emerging insights in Multiple Myeloma diagnostics.

We’re grateful for the oral and poster sessions that showcased groundbreaking research, and conversations that continue to shape the future of monoclonal gammopathies. We look forward to building on these connections, strengthening our collaborations and continuing to drive diagnostic innovation into 2026.

New research using EXENT® System featured at ! The latest data from researchers in the United States, highlights how th...
08/12/2025

New research using EXENT® System featured at !

The latest data from researchers in the United States, highlights how the EXENT System can provide deeper insights into IgM monoclonal proteins in familial Waldenström’s macroglobulinemia (WM) cases.

We’re proud to see this work incorporating the EXENT System represented at ASH and look forward to exploring the findings further during Monday’s poster session (5:30 – 7:30 PM).

The landscape of plasma cell disorders continues to evolve, moving beyond the traditional ‘undetermined significance’ of...
08/12/2025

The landscape of plasma cell disorders continues to evolve, moving beyond the traditional ‘undetermined significance’ of MGUS towards growing recognition of monoclonal gammopathies of clinical significance (MGCS).

We are looking forward to attending today’s ASH session in OCCC - West Hall E2 (4:30–5:45 PM), where leading experts will share the latest insights on:

▪️ Diagnosing and managing POEMS syndrome
▪️ Understanding monoclonal gammopathy of renal significance (MGRS)
▪️ Addressing monoclonal gammopathy of neurologic significance (MGNS)

To understand more on MGCS, take a look at our dedicated MGCS webpage here: http://spr.ly/61877CBBb

Two posters presented at ASH 2025 highlight how pivotal the SLiM criteria have been in transforming myeloma care. For pa...
08/12/2025

Two posters presented at ASH 2025 highlight how pivotal the SLiM criteria have been in transforming myeloma care.

For patients with MGUS (poster 3972), the introduction of the SLiM criteria has led to increased evaluation for myeloma defining events and lower monoclonal protein at the time of first biopsy, showing that patients are being assessed earlier in their disease course.

In newly diagnosed myeloma patients (poster 6378), the rise in the use of SLiM biomarkers supported earlier diagnosis and resulted in fewer patients presenting with CRAB related organ damage.

Our scientific team is attending a poster session this evening, connecting with colleagues and discussing the latest adv...
07/12/2025

Our scientific team is attending a poster session this evening, connecting with colleagues and discussing the latest advances in the monoclonal gammopathy field.

Visit us at booth 2171 before 2pm tomorrow connect with our scientific team.

At this year’s ASH, researchers from the nationwide NoMoreMGUS project are challenging long-standing ‘undetermined signi...
07/12/2025

At this year’s ASH, researchers from the nationwide NoMoreMGUS project are challenging long-standing ‘undetermined significance’ in MGUS.

Across 31 Spanish hospitals, this large-scale study is exploring minimally invasive biomarkers to identify patients at higher risk of malignant transformation.

Early findings reveal that measuring circulating tumor cells (CTCs) alongside M-protein concentration and sFLC ratio can better identify patients at higher risk of transformation, helping define a new category of MGUS: monoclonal gammopathies of malignant significance.

We are looking forward to hearing more about it from Dr Bruno Paiva today at 12.15 in OCCC - West Hall E2.

Address

8 Calthorpe Road, Edgbaston
Birmingham
B151QT

Opening Hours

Monday 7:30am - 5pm
Tuesday 7:30am - 5pm
Wednesday 7:30am - 5pm
Thursday 7:30am - 5pm
Friday 7:30am - 5pm

Telephone

+441214569500

Website

Alerts

Be the first to know and let us send you an email when The Binding Site posts news and promotions. Your email address will not be used for any other purpose, and you can unsubscribe at any time.

Contact The Practice

Send a message to The Binding Site:

Shortcuts

Share

Share on Facebook Share on Twitter Share on LinkedIn
Share on Pinterest Share on Reddit Share via Email
Share on WhatsApp Share on Instagram Share on Telegram

Category